Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewAmsterdam Pharma Company N.V. filings document a late-stage clinical biopharmaceutical issuer developing oral, non-statin therapies for cardiovascular-risk patients with elevated LDL-C. Its Form 8-K reports furnish financial results, corporate updates, investor presentations and clinical-program disclosures involving obicetrapib, including its use alone and with ezetimibe.
The company’s SEC record also covers proxy governance, executive compensation, equity awards, director and officer matters, compensatory arrangements and Nasdaq-listed securities. Cover-page disclosures identify ordinary shares under NAMS and warrants under NAMSW, while material-event filings record Regulation FD presentations, leadership-related agreements and public-company capital-structure information.
NewAmsterdam Pharma Company N.V. furnished an updated investor presentation that highlights the development and commercialization plans for its CETP inhibitor obicetrapib.
The company describes obicetrapib as a once-daily oral therapy that produced LDL-C reductions of about 35–40% as monotherapy and roughly 50–60% when combined with ezetimibe across multiple Phase 2 and Phase 3 trials, with additional ~45% Lp(a) lowering versus placebo in pooled analyses. Exploratory analyses from the Phase 3 BROADWAY trial showed an observed 21% reduction in major adverse cardiovascular events at one year versus placebo, with pooled BROADWAY and BROOKLYN data also favoring obicetrapib, while noting these studies were not powered for outcomes.
The presentation outlines a potential global peak sales opportunity of more than $8 billion for cardiometabolic use, citing over 30 million U.S. patients on lipid-lowering drugs who are not at LDL-C goal. It also reports cash, cash equivalents and marketable securities of approximately $729 million at year-end 2025, intended to support a prospective U.S. launch if approved. Additional data show a 2.84% treatment benefit on p‑tau217 progression overall and a 20.5% benefit in ApoE4 homozygotes over 12 months, along with favorable changes in other Alzheimer’s biomarkers. The company emphasizes intellectual property protection, including composition-of-matter coverage extending into 2043, and a broad late-stage clinical program, including the PREVAIL cardiovascular outcomes trial and multiple Phase 3 and Phase 2 studies.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported a multi-day option exercise-and-sell transaction from February 24 through February 26, 2026, under a Rule 10b5-1 trading plan. He exercised options for 306,293 ordinary shares at EUR 1.16392 per share and sold 306,293 shares at prices ranging from $33.63 to $36.68 per share.
The filing also reports a February 26 transfer of 285,715 ordinary shares to a grantor retained annuity trust (GRAT). Following the transactions, Davidson held 174,144 ordinary shares directly and 285,715 shares indirectly through the GRAT, with 682,974 options remaining under the reported grant.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein reported open-market sales of company ordinary shares. On February 20, 2026, he sold 14,692 shares at a weighted average price of $35.00 per share and 30,789 shares at a weighted average price of $35.46 per share. The filing notes that these sales occurred through multiple trades, with prices ranging from $34.24 to $35.23 for the first block and from $35.24 to $35.86 for the second block. Following these transactions, he directly owned 53,500 ordinary shares of NewAmsterdam Pharma.
NewAmsterdam Pharma Company N.V. reported a Rule 144 notice for a sale of 6,000 ordinary shares. The sale was reported by Johannes Jacob Pieter Kastelein with a transaction date of 01/05/2026 and proceeds shown as $199,500.
NewAmsterdam Pharma Company N.V. files its annual report describing a late-stage biopharma business built around obicetrapib, an oral CETP inhibitor aimed at lowering LDL cholesterol in high‑risk cardiovascular patients who are not at goal on statins.
Multiple Phase 3 trials (BROADWAY, BROOKLYN and TANDEM) met primary and secondary endpoints with statistically significant LDL-C reductions and safety broadly comparable to placebo. A large cardiovascular outcomes trial, PREVAIL, is underway to evaluate major adverse cardiovascular event benefit.
The company has partnered with Menarini in most of Europe, receiving a €115 million upfront payment, committed €27.5 million R&D funding and potential milestones up to €863 million, plus tiered royalties. EMA, UK and Swiss regulators are reviewing marketing applications, with decisions anticipated in the second half of 2026. A broad patent estate could protect obicetrapib and combinations into the 2040s, and early work is exploring its use in Alzheimer’s disease.
NewAmsterdam Pharma reported full year 2025 results and highlighted progress advancing its cholesterol drug obicetrapib. Revenue was $22.5 million, down from $45.6 million in 2024, while the net loss narrowed to $203.8 million from $241.6 million as R&D expenses declined.
Cash, cash equivalents and marketable securities totaled $728.9 million at December 31, 2025, which the company expects will fund operations through the PREVAIL cardiovascular outcomes readout and, if approved, support a potential U.S. launch. Marketing applications for obicetrapib and a fixed-dose combination with ezetimibe have been accepted in Europe, the UK and Switzerland, with decisions anticipated in the second half of 2026.
The company is running three Phase 3 trials—PREVAIL, REMBRANDT and RUBENS—and plans to start a trial of obicetrapib in early Alzheimer’s disease in 2026 following positive Alzheimer’s biomarker data from the BROADWAY study.
NewAmsterdam Pharma Co N.V. received an updated Schedule 13G/A (Amendment No. 3) from investment entities affiliated with Viking Global, disclosing their passive ownership in the company’s ordinary shares.
The Viking-related entities collectively report beneficial ownership of 4,203,567 ordinary shares, representing 3.7% of the outstanding class, based on 113,390,804 ordinary shares outstanding as of October 31, 2025. The shares are held through two main limited partnerships, which directly own 2,817,205 and 1,386,362 ordinary shares, respectively. Key individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are reported as having shared voting and dispositive power over these holdings through their roles in Viking’s general partner and parent entities.
The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of NewAmsterdam Pharma, indicating a passive investment stance under the 13G framework.
FMR LLC has filed a Schedule 13G reporting beneficial ownership of 6,412,984 shares of Pharma Company NV common stock, representing 5.7% of the class as of the event date. FMR has sole voting power over 6,403,075 shares and sole dispositive power over 6,412,984 shares.
Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same 6,412,984 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pharma Company NV.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026. On January 27, 2026, she exercised 39,816 options at an exercise price of $10.90 per ordinary share and acquired the same number of ordinary shares.
That same day she sold 39,816 ordinary shares at a weighted average price of $32.62 per share, leaving 24,353 ordinary shares directly owned afterward. On January 28, 2026, she exercised another 32,612 options at $10.90 per share and acquired 32,612 ordinary shares, then sold 32,612 ordinary shares at a weighted average price of $31.80 per share.
After these transactions, she directly held 24,353 ordinary shares and 73,134 options (options with a $10.90 exercise price and an expiration date of January 1, 2033). The filing notes that the sale prices are weighted averages across multiple trades within the stated price ranges.